Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008991 | 0.74 | RAF1 (0.56) | RAF1RIPK2ABL1MAPK13MAPK14 | |
| SCHEMBL1378323 | 0.73 | ALDH1A1 (0.49) | TP53MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL3166302 | 0.72 | SRC (0.72) | SRCRAF1ABL1MAPK13MAPK14 | |
| SCHEMBL3044827 | 0.72 | CACNA1G (0.48) | KDRBRAFMAPTSMN1; SMN2 | |
| SCHEMBL14173408 | 0.71 | FLT3 (0.57) | MAP3K7PDGFRBABL1MAPK14TP53 | |
| SCHEMBL13528824 | 0.71 | SRC (0.60) | SRCRAF1RIPK2MAPK13MAPK14 | |
| SCHEMBL8102374 | 0.69 | PDGFRB (0.65) | SRCMAP3K7PDGFRBABL1KDR | |
| SCHEMBL5910689 | 0.69 | MAPT (0.85) | TP53MAPTLMNA | |
| SCHEMBL19911109 | 0.68 | SRC (1.00) | SRCMAP3K7PDGFRBRAF1RIPK2 | |
| SCHEMBL3183537 | 0.67 | MAPT (0.56) | RAF1MAPK13MAPK14KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| EP-1379505-B1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | claimed |
| EP-1379505-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | SRC 939/4885MAP3K7 129/4885PDGFRB 117/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | SRC 58/4885MAP3K7 11/4885PDGFRB 25/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | SRC 939/4885MAP3K7 129/4885PDGFRB 117/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | SRC 939/4885MAP3K7 129/4885PDGFRB 117/4885 |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | SRC 363/4885MAP3K7 20/4885PDGFRB 2999/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | SRC 939/4885MAP3K7 129/4885PDGFRB 117/4885 |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | SRC 3666/4885MAP3K7 4542/4885PDGFRB 3206/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | SRC 589/4885MAP3K7 99/4885PDGFRB 137/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | SRC 939/4885MAP3K7 129/4885PDGFRB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.